ATRC

AtriCure, Inc.

AtriCure, Inc. is classed by the SEC under Surgical & Medical Instruments & Apparatus (industry code 3841), based in Mason, OH. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $535 million and a loss of $11 million (its filed statements).

Product business Surgical & Medical Instruments & Apparatus Mason, OH filings since 2005 9 of 9 filed

Sector peers: UFPTBVSLMATATEC

6.6/10headline grade
vs its business-model standard

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3841, Surgical & Medical Instruments & Apparatus); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 6.6 out of ten, 9 of 9 metrics filed: past 5.9 out of ten, present 7.4 out of ten, future 6.3 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 8.3 out of ten. No warning events in its filings since 2017. 83rd percentile among 121 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 5.2 out of ten. +14.7% a year over 10 filed years; profitable in 1 of 10. 52nd percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 3.7 out of ten. Share count grew 1.4% a year. 0% of cash flow returned. Insiders: 17 sales, 0 purchases. 37th percentile among 40 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 7.3 out of ten. ROE -2%: lost 2¢ per shareholder dollar. Leverage 25%: owes 25¢ per asset dollar. 73rd percentile among 120 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 6.6 out of ten. top 34% of 109 in its family; net margin -2.1%. 66th percentile among 109 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 8.6 out of ten. top 14% of 90 in its family for leadership; chief executive since 2012. 86th percentile among 90 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 6.8 out of ten. top 32% of 104 in its family for room to expand. 68th percentile among 104 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 5.9 out of ten. top 41% of 105 in its family for growth drivers. 59th percentile among 105 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 5.8 out of ten. top 42% of 88 in its family for expectations against reality. 58th percentile among 88 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-19 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-27 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-07-23 (on EDGAR). Newest filing: Form SCHEDULE 13G/A, 2026-10-05. Filings on record since 2005. Read from EDGAR 2026-10-12.

Where the revenue comes from

By geography: United States 81%, Europe 12%, Asia-Pacific 6%, Other International 1%. As tagged in its annual report (Form 10-K, filed 2026-02-19).

Who runs it

Carrel, Michael H (President, CEO, & Director); Wirick, Angela L (Chief Financial Officer); Seith, Douglas J (Chief Operating Officer); Privitera, Salvatore (Chief Technical Officer); Dahlquist, Karl S. (Chief Legal Officer); Doraiswamy, Vinayak (Chief Scientific Officer); Noznesky, Justin J (Chief Mktg & Strategy Officer); Groves, Regina E (director); Prange, Karen (director); Yuen, Maggie (director); and 5 more. 15 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.